HTFL — HeartFlow, Inc. Stock Price, Chart & AI Report

Positive Mar 27, 2026 • 13:30 UTC Benzinga • Usa News Group

How Decentralized AI is Unlocking Value in Cardiac Diagnostics

Five companies—VentriPoint Diagnostics, HeartBeam, Heartflow, Hyperfine, and GE Healthcare Technologies—are advancing AI-enabled cardiac diagnostic platforms to address the global heart disease crisis. Recent developments include VentriPoint's partnership with First Light Health for remote Indigenous communities, HeartBeam's collaboration with Mount Sinai on AI-ECG algorithms, Heartflow's new clinical registry data, Hyperfine's breakthrough stroke detection results, and GE Healthcare's role in the EU's COMPASS cardiotoxicity initiative.

BEAT BEATW HTFL HYPR AI-enabled diagnostics cardiac imaging decentralized healthcare remote care delivery

Sentiment note

New clinical evidence from 15,000-patient registry showing plaque volume predictive value, plus enrollment in 5,000-patient NAVIGATE-PCI Registry, strengthens real-world evidence base and supports expansion into guided intervention planning.

Neutral Mar 25, 2026 • 19:03 UTC The Motley Fool • Jonathan Ponciano

What Investors Should Know About One HeartFlow Insider's $2 Million Stock Sale

HeartFlow's chief medical officer Rogers Campbell sold 64,533 shares worth approximately $1.66 million on March 19, 2026, reducing his direct holdings by 72.8%. The sale appears routine and executed under a pre-arranged plan rather than signaling loss of confidence. HeartFlow reported strong 2025 revenue growth of 40% year-over-year to $176 million, with 2026 guidance of $218-222 million, though the company remains unprofitable.

HTFL insider trading stock sale HeartFlow AI-powered diagnostics revenue growth SEC Form 4 cardiac imaging

Sentiment note

While the insider sale reduced direct holdings significantly (72.8%), the article characterizes it as routine and mechanical rather than a loss of confidence. The company demonstrates strong operational momentum with 40% YoY revenue growth, expanding margins approaching 80%, and positive 2026 guidance for continued double-digit growth. However, the company remains unprofitable with net losses of $125.4 million TTM, and the flat stock performance over the past year suggests investor caution despite growth metrics.

Neutral Dec 28, 2025 • 06:08 UTC The Motley Fool • Robert Izquierdo

Is Recent IPO Stock Heartflow a Buy After a Director Scooped Up Shares Worth Over $1 Million?

HeartFlow director Jeffrey Lightcap purchased 40,000 shares worth $1.05 million on December 16, 2025, just after the stock hit a 52-week low of $25.38. While the company shows strong revenue growth of 41% year-over-year in Q3, it faces significant profitability challenges with net losses expanding to $50.9 million. The insider buy suggests confidence in the company's future, but the stock remains risky for investors given its recent IPO status and limited public company track record.

HTFL insider buying IPO cardiac diagnostics AI-driven diagnostics revenue growth net losses director purchase

Sentiment note

Mixed signals: positive insider buying and strong 41% YoY revenue growth suggest confidence, but significant net losses ($50.9M in Q3) and recent IPO status with limited track record create substantial risk. The article concludes it's only suitable for high-risk tolerance investors, indicating cautious optimism rather than a clear buy recommendation.

Positive Nov 9, 2025 • 18:30 UTC GlobeNewswire Inc. • Timothy Fairbairn, Ph.D.

AHA 2025: Late-Breaking Data Reinforce the Prognostic Power of AI-Driven Heartflow Plaque Analysis as the Most Clinically Validated Framework for Coronary Risk Stratification

Heartflow presented late-breaking data at AHA 2025 demonstrating that total plaque volume can predict cardiovascular events with high accuracy, showing patients in the highest plaque volume stage have over 5x greater risk of major cardiovascular events.

HTFL AI coronary artery disease plaque analysis cardiovascular risk medical technology

Sentiment note

Company presented groundbreaking research showing significant predictive power of their AI-driven plaque analysis technology, with potential to improve cardiovascular disease management and patient outcomes